profound trial shows increased rpfs in mcrpc patients with brca1, brca2, and atm mutations
Published 4 years ago • 742 plays • Length 16:07Download video MP4
Download video MP3
Similar videos
-
16:22
role of parp inhibitors in prostate cancer
-
33:19
castration resistant prostate cancer - developments and challenges from 2020
-
12:36
pca commentary - parp inhibition w/ olaparib: potential new indication for first-line mcrpc therapy
-
16:39
clinical case discussion: metastatic prostate cancer and evidence for more precision therapy
-
10:51
advanced prostate cancer clinical trials update 2022
-
14:14
management of mcrpc in china
-
9:02
chemotherapy for brca-mutated prostate cancer
-
9:59
profound performance: olaparib vs. enzalutamide or abiraterone for hrr altered mcrpc
-
9:43
transperineal biopsy & classification of risk using novel gleason pattern quantification
-
5:07
response to olaparib among men with brca 1 / 2 or atm mutated prostate cancer
-
3:57
germline atm vs brca2 mutations affecting therapy outcomes in prostate cancer
-
49:55
yale cancer center grand rounds | june 8, 2021
-
10:42
advanced prostate cancer: what's changing
-
21:53
identifying mutations and optimizing use of parp inhibitors
-
3:49
the role of targeting dna repair mutations in advanced prostate cancer
-
13:55
implementation of germline testing for prostate cancer philadelphia prostate cancer consensus confe
-
18:21
decisional tools to determine need for biopsy and re-biopsy in men with elevated psas
-
3:59
universal screening for brca1 and brca2 mutations
-
22:43
molecular insights into the germline for prostate cancer initiation, progression, and aggressiveness